Medical Use
TAFINLAR™ is a kinase inhibitor prescribed as a monotherapy for patients with unresectable or metastatic melanoma that carries the BRAF V600E mutation, as identified by an FDA-approved test.
When used in combination with trametinib, TAFINLAR™ is indicated for treating patients with unresectable or metastatic melanoma that has either BRAF V600E or V600K mutations, as confirmed by an FDA-approved test. The combination therapy is supported by evidence of a durable response rate.
Warning & Precautions
Before starting dabrafenib, inform your doctor or pharmacist if you have any allergies, including to this medication. Some inactive ingredients in dabrafenib could trigger allergic reactions or other issues. Your pharmacist can provide more details.
Share your medical history with your doctor or pharmacist, especially if you have conditions like G6PD deficiency, liver disease, or diabetes.
If you are scheduled for surgery, let your doctor or dentist know about all the products you are using, including prescription, nonprescription, and herbal products.
If you are pregnant or planning to become pregnant, inform your doctor. Dabrafenib can harm an unborn baby, so you should avoid becoming pregnant while on this medication. Your doctor will likely order a pregnancy test before you begin treatment. Both men and women should discuss reliable non-hormonal birth control options, such as condoms or a diaphragm with spermicide, to use during treatment and for two weeks after the last dose. If pregnancy occurs, contact your doctor immediately to discuss the risks and benefits.
Since dabrafenib can be absorbed through the skin and lungs and may harm an unborn baby, pregnant women or those who may become pregnant should not handle the medication or inhale the dust from the capsules. It is not known if dabrafenib passes into breast milk, so breastfeeding is not recommended during treatment and for two weeks after the last dose. Consult your doctor before breastfeeding.
Documentation Availability
Documents required to import TAFINLAR to India?
TAFINLAR can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing TAFINLAR around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the generic name for TAFINLAR®?
The generic name for TAFINLAR® is dabrafenib.
Who manufactures TAFINLAR®?
TAFINLAR® is manufactured by Novartis.
Is TAFINLAR® approved by the FDA?
Yes, TAFINLAR® was approved by the FDA in 2013.
What dosage forms are available for TAFINLAR®?
TAFINLAR® is available in capsule form, with dosages of 50 mg and 75 mg.
How to order TAFINLAR® online in India?
TAFINLAR® can be ordered online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
